Sign in →

Test Code SPSA Prostate Specific Antigen, Total (Screening)

Important Note

This test may be affected by biotin interference. Patients on high dose biotin (5mg/day or more) should not have samples drawn until at least 24 hours after the last biotin administration.

Specimen and Container/Tube

Plasma

Rejection Criteria

Whole blood/unspun samples greater than 6 hours will be
rejected.

Turnaround Time

N/A

Test Includes

N/A

Specimen Type

Plasma

Preferred Volume

0.5 mL

UCMC Collection Instructions

1. Collect sample following standard collection methods
2. Within 2 hours of collection the sample must be received in
Laboratory Service Center
3. Transport room temperature (15 – 25˚C)

Test Usage

Use for screening when no disease or symptoms indicated.

Indicated for the measurement of total PSA in conjunction with
digital rectal examination (DRE) as an aid in the detection of
prostate cancer in men aged 50 years or older. Prostate biopsy is
required for diagnosis of prostate cancer. The test is further
indicated for serial measurement of PSA to aid in the management of
cancer patients.

Critical Results

N/A

Test Limitations

The measured PSA value of a
patient���s sample can vary
depending on the testing procedure used. PSA values determined on
patient samples by different testing procedures cannot be
directly
compared with one another and could be the cause of erroneous
medical interpretations. An inflammation or trauma of the
prostate
(e.g. in cases of urinary retention or following rectal
examination, cystoscopy, coloscopy, transurethral biopsy, laser
treatment or ergometry) can lead to PSA
elevations of varying
duration and magnitude. It is known that in rare cases PSA isoforms
do exist which may be measured differently by different
PSA tests.
Findings of this kind have occasionally been reported for
PSA tests
from various manufacturers.

Fee Code

69199

Container/Tube

Li-Heparin, Mint Green Top

Specimen Minimum Volume

0.2 mL

Day(s) Performed

24 hours, 7 days a week including holidays.

STAT DAY(S) AND TIME(S) PERFORMED

N/A

CPT

G0103

Method Name

Electrochemiluminescence Immunoassay
(ECLIA)

Reference Values

<4.0 ng/mL

Reject Due To

Whole blood/unspun samples greater than 6 hours will be
rejected.

STAT Turnaround Time

N/A

Synonyms

N/A

Offsite Collection Instructions

1. Collect sample following standard collection methods
2. Within 2 hours of collection the sample must be spun and
aliquoted
3. Transport refrigerated (2 – 8˚C)

Additional Information

Use for screening when no disease or symptoms indicated.

There is no high-dose hook effect at Total PSA concentrations up
to 17,000 ng/mL.

Included in Additional codes

PSAB

Coverage Information

CMS has established a national coverage policy (NCD) for
Medicare for this test as of November 25, 2002. Please document
medical necessity.

Typically only covered when total PSA is in the 2.6-10.0 ng/mL
range, DRE is normal and there is either a contraindication to
biopsy or the patient has had an initial biopsy that was
negative.

Stability: Room Temp

n/a

Stability: Refrigerated

5 days

Stability: Frozen

6 months

Pediatric Volume

0.2 mL

Clinical Indications

Use for screening when no disease or symptoms indicated.

Indicated for the measurement of total PSA in conjunction with
digital rectal examination (DRE) as an
aid in the detection of
prostate cancer in men aged 50 years or older. Prostate biopsy
is
required for diagnosis of prostate cancer. The test is further
indicated for serial measurement of PSA
to aid in the management of
cancer patients.

Transport Instructions

1. Collect sample following standard collection methods
2. Within 2 hours of collection the sample must be spun and
aliquoted
3. Transport?�refrigerated?�(2 �?? 8??C)

Test Components

N/A

Specimen Stability

n/a

Methodology

Electrochemiluminescence Immunoassay
(ECLIA)

Synonyms/Key Search Words

N/A